Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05952557 |
| Title | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) |
| Acronym | CAMBRIA-2 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS |